浙江省丽水市中医院,浙江省丽水市中山街800号,323000
fountani@163.com
收稿:2023-09-09,
修回:2023-11-10,
纸质出版:2024-01-17
移动端阅览
李诗国,潘铨,江丽平等.畲药地稔滋肾方联合针刺辅助治疗原发性胆汁性胆管炎肝肾阴虚证32例临床观察[J].中医杂志,2024,65(02):198-204.
LI Shiguo,PAN quan,JIANG Liping,et al.She Medicine (畲药) Diren Zishen Formula (地稔滋肾方) Combined with Acupuncture as Adjunctive Treatment for 32 Cases of Primary Biliary Cholangitis with Liver and Kidney Yin Deficiency Syndrome[J].Journal of Traditional Chinese Medicine,2024,65(02):198-204.
李诗国,潘铨,江丽平等.畲药地稔滋肾方联合针刺辅助治疗原发性胆汁性胆管炎肝肾阴虚证32例临床观察[J].中医杂志,2024,65(02):198-204. DOI: 10.13288/j.11-2166/r.2024.02.014.
LI Shiguo,PAN quan,JIANG Liping,et al.She Medicine (畲药) Diren Zishen Formula (地稔滋肾方) Combined with Acupuncture as Adjunctive Treatment for 32 Cases of Primary Biliary Cholangitis with Liver and Kidney Yin Deficiency Syndrome[J].Journal of Traditional Chinese Medicine,2024,65(02):198-204. DOI: 10.13288/j.11-2166/r.2024.02.014.
目的
2
观察畲药地稔滋肾方联合针刺辅助治疗原发性胆汁性胆管炎肝肾阴虚证的临床疗效及安全性。
方法
2
将70例原发性胆汁性胆管炎肝肾阴虚证患者随机分为对照组和治疗组各35例。对照组给予口服熊去氧胆酸胶囊(每次250 mg、每日3次);治疗组在对照组治疗的基础上给予口服畲药地稔滋肾方汤剂(每日1剂,分早晚两次各200 ml温服)联合针刺治疗(选穴取双侧三阴交、太冲、肝俞、足三里、丰隆,每日1次,每周连续5日),疗程均为3个月。比较两组治疗前后皮肤瘙痒、乏力、黄疸、胁痛4种中医症状评分及中医证候积分,肝功能指标[门冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、碱性磷酸酶(ALP)、γ-谷氨酰转移酶(GGT)、总胆红素(TBiL)],肝纤维化指标[血清层粘连蛋白(LN)、血清透明质酸酶(HA)、血清Ⅳ型胶原(Ⅳ-C)、血清Ⅲ型前胶原(PC-Ⅲ)]以及炎症因子指标[血清白细胞介素6(IL-6)、肿瘤坏死因子α(TNF-α)],治疗后统计中医证候疗效,并进行安全性评价。
结果
2
最终纳入疗效分析治疗组32例,对照组31例。治疗组中医证候总有效率(87.50%,28例/32例)高于对照组(67.74%,20例/31例)(
P
<0.05)。治疗后两组中医各项症状评分及证候积分、肝功能及肝纤维化各项指标均较治疗前明显降低,治疗组炎症因子指标较治疗前降低,且治疗组上述各项指标改善效果均优于对照组(
P
<0.05或
P
<0.01)。两组安全性良好,未出现不良反应。
结论
2
畲药地稔滋肾方联合针刺辅助治疗能显著提高原发性胆汁性胆管炎患者的临床疗效,改善肝功能,减轻炎症反应,缓解肝纤维化,且安全性好。
Objective
2
To observe the clinical effectiveness and safety of
She medicine
(畲药)
Diren Zishen Formula
(地稔滋肾方) combined with acupuncture as adjunctive treatment for primary biliary cholangitis with liver and kidney
yin
deficiency syndrome.
Methods
2
Seventy patients of primary biliary cholangitis with liver and kidney
yin
deficiency syndrome were randomly divided into a control group and a treatment group, with 35 patients in each group. The control group received oral ursodeoxycholic acid capsules (250 mg per dose, three times daily). The treatment group received
She medicine
Diren Zishen Formula
oral decoction (one dose daily, 200 ml per dose in the morning and evening, served warm) and acupuncture [bilateral Sanyingjiao (SP6), Taichong (LR3), Ganshu (BL18), Zusanli (ST36), Fenglong (ST17), once daily, 5 consecutive days per week] in addition to the same treatment as the control group. The treatment duration was three months for both groups. Comparisons were made between the two groups before and after treatment for the following parameters, which were four traditional Chinese medicine (TCM) symptoms scores (skin itching, fatigue, jaundice, and flank pain), TCM syndrome scores, liver function indicators including aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT) and total bilirubin (TBiL), liver fibrosis markers including serum laminin (LN), serum hyaluronic acid (HA), serum type Ⅳ collagen (Ⅳ-C) and serum type Ⅲ procollagen (PC-Ⅲ), and inflammatory factor indicators including serum interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α). The effectiveness of TCM syndrome between the two groups was compared and safety evaluations were also conducted after treatment.
Results
2
A total of 32 cases were finally analyzed in the treatment group, while the control group had 31 cases. The total effective rate of TCM syndrome in the treatment group (87.50%, 28/32) was higher than that in the control group (67.74%, 20/31) (
P
<0.05). After treatment, the TCM symptom scores, syndrome scores, liver function, and liver fibrosis markers in both groups signi-ficantly decreased, while in the treatment group, the inflammatory factor indicators decreased after treatment, and more decreases were found than those in the control group (
P
<0.05 or
P
<0.01). Both groups had good safety, and no adverse reactions were observed.
Conclusion
2
The combination of
She medicine
Diren Zishen Formula
and acupuncture as an adjunctive treatment for primary biliary cholangitis can significantly improve the clinical effectiveness, improve liver function, reduce inflammatory response, and alleviate liver fibrosis, with good safety.
中华医学会肝病学分会 . 原发性胆汁性胆管炎的诊断和治疗指南(2021) [J]. 临床肝胆病杂志 , 2022 , 38 ( 1 ): 35 - 41 .
WONG KA , BAHAR R , LIU CH , et al . Current treatment options for primary biliary cholangitis [J]. Clin Liver Dis , 2018 , 22 ( 3 ): 481 - 500 .
吕行 , 李婷 , 孙晓东 , 等 . 原发性胆汁性胆管炎的治疗进展 [J]. 临床肝胆病杂志 , 2022 , 38 ( 9 ): 2130 - 2135 .
孙雪 , 陈新瑜 . 中西医治疗原发性胆汁性胆管炎的研究概况 [J]. 中国民间疗法 , 2022 , 30 ( 1 ): 119 - 122 .
姚佳敏 , 过建春 . 原发性胆汁性胆管炎中医病机认识及治疗进展 [J]. 中西医结合肝病杂志 , 2021 , 31 ( 11 ): 1051 - 1053 .
游丽萍 , 郑超 , 高月求 , 等 . 自免方联合熊去氧胆酸治疗肝肾阴虚证原发性胆汁性胆管炎随机对照研究 [J]. 中国中西医结合杂志 , 2023 , 43 ( 3 ): 292 - 297 .
何晓瑾 , 王浩 , 王磊 , 等 . 原发性胆汁性胆管炎的中医治疗 [J]. 中医杂志 , 2019 , 60 ( 1 ): 75 - 76,87 .
郑筱萸 . 中药新药临床研究指导原则(试行) [M]. 北京 : 中国医药科技出版社 , 2002 : 143 - 149 .
肖丽娟 , 宋亦诚 , 王劲秋 , 等 . 桃红二至煎治疗原发性胆汁性胆管炎临床研究 [J]. 中西医结合肝病杂志 , 2023 , 33 ( 6 ): 496 - 499 .
王瑞平 . 随机对照临床试验设计中的样本量估算方法 [J]. 上海医药 , 2023 , 44 ( 1 ): 48 - 52 .
郑玥琪 , 陈建杰 , 陈逸云 , 等 . 原发性胆汁性胆管炎中医证型与证素分布特点文献分析 [J]. 临床肝胆病杂志 , 2018 , 34 ( 4 ): 814 - 819 .
焦云 , 周毅骏 . 190例原发性胆汁性胆管炎患者临床指标及影响不良预后的危险因素分析 [J]. 中国现代医生 , 2023 , 61 ( 2 ): 21 - 24 .
沈斐斐 , 陆伦根 . 肝脏碱性磷酸酶:胆汁淤积和胆道损伤的标志物 [J]. 临床肝胆病杂志 , 2016 , 32 ( 5 ): 1026 - 1030 .
MURILLO PEREZ CF , HARMS MH , LINDOR KD , et al . Goals of treatment for improved survival in primary biliary cholangitis: treatment target should be bilirubin within the normal range and normalization of alkaline phosphatase [J]. Am J Gastroenterol , 2020 , 115 ( 7 ): 1066 - 1074 .
屈瑶 , 张玮 . 细胞凋亡在原发性胆汁性胆管炎发病机制中的作用 [J]. 临床肝胆病杂志 , 2019 , 35 ( 6 ): 1397 - 1400 .
王璐 , 韩英 . 原发性胆汁性胆管炎的诊治现状与挑战 [J]. 临床肝胆病杂志 , 2021 , 37 ( 10 ): 2257 - 2261 .
孔祥云 , 朱玉侠 , 韩者艺 , 等 . AIH-PBC重叠综合征患者的免疫学、炎症因子特征及其与肝功能的相关性 [J]. 海南医学 , 2022 , 33 ( 23 ): 2993 - 2996 .
黄祎 , 许国圣 , 杨浦娟 , 等 . 滋水涵木利胆方对肝肾亏虚型原发性胆汁性胆管炎患者外周血辅助性T淋巴细胞17及相关细胞因子的影响 [J]. 河北中医 , 2022 , 44 ( 5 ): 748 - 753 .
梁霄龙 , 李诗国 , 戴圣伟 . 二甲软肝汤联合拉米夫定治疗慢性乙型肝炎肝纤维化42例临床观察 [J]. 浙江中医杂志 , 2019 , 54 ( 1 ): 48 - 49 .
0
浏览量
0
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010102007558号